Scarica l'app Stockscreener
2.64
6.45%
0.16
Dopo l'orario di chiusura:
2.64
Precedente Chiudi:
$2.48
Aprire:
$2.56
Volume 24 ore:
1.37M
Relative Volume:
0.85
Capitalizzazione di mercato:
$24.91M
Reddito:
$356.60K
Utile/perdita netta:
$-25.97M
Rapporto P/E:
-0.1847
EPS:
-14.29
Flusso di cassa netto:
$-25.22M
1 W Prestazione:
+7.32%
1M Prestazione:
+12.34%
6M Prestazione:
-8.97%
1 anno Prestazione:
-52.98%
Intervallo 1D:
$2.48
$2.64
Intervallo di 1 settimana:
$2.27
$2.75
Portata 52W:
$1.0901
$11.18
Geovax Labs Inc Stock (GOVX) Company Profile
Nome
Geovax Labs Inc
Settore
Industria
Telefono
678-384-7220
Indirizzo
1900 LAKE PARK DRIVE, SMYRNA
Confronta GOVX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GOVX
Geovax Labs Inc
|
2.64 | 24.91M | 356.60K | -25.97M | -25.22M | -14.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.11 | 104.84B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.15 | 78.92B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
621.29 | 37.15B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.28 | 30.22B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
115.79 | 27.76B | 3.30B | -501.07M | 1.03B | -2.1146 |
Geovax Labs Inc Stock (GOVX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-11 | Iniziato | Alliance Global Partners | Buy |
| 2024-07-16 | Iniziato | ROTH MKM | Buy |
| 2020-11-19 | Iniziato | Maxim Group | Buy |
Geovax Labs Inc Borsa (GOVX) Ultime notizie
Contrasting GeoVax Labs (NASDAQ:GOVX) & Silverback Therapeutics (NASDAQ:SBTX) - Defense World
GeoVax Labs, Inc. (NASDAQ:GOVX) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
GeoVax adjourns Special Meeting due to low quorum - Investing.com
GeoVax adjourns Special Meeting due to low quorum By Investing.com - Investing.com Australia
GeoVax Receives Notice of Allowance For Cancer Vaccine Patent - The Manila Times
GeoVax Labs Secures Key Cancer Vaccine Patent, Reports Breakthrough 100% Tumor Prevention Data - StockTitan
GeoVax Labs (GOVX) Price Target Increased by 1170.83% to 77.78 - MSN
GeoVax Labs, Inc. (NASDAQ:GOVX) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Geovax Labs (FRA:E8LA) Days Inventory : 0.00 (As of Sep. 2024) - GuruFocus.com
Geovax Labs (STU:E8LA) Forward Dividend Yield % : 0.00% (As of Nov. 30, 2024) - GuruFocus.com
Alliance Global Partners Initiates Coverage of GeoVax Labs (GOVX) with Buy Recommendation - MSN
3 Penny Stocks Ready to Break Out in 2025 - sharewise
Geovax Labs (GOVX-Q) QuotePress Release - The Globe and Mail
Geovax Labs (STU:E8LA) Momentum Rank : 5 (As of Nov. 27, 2024) - GuruFocus.com
GeoVax to Present at the Noble Capital Markets Twentieth Annual Emerging Growth Equity Conference - GlobeNewswire
GeoVax CEO to Present COVID-19 Vaccine & Cancer Therapy Updates at NobleCon20 | GOVX Stock News - StockTitan
GeoVax, SIGA Jump After WHO Extends Mpox Public Emergency Status: Here’s What Retail Thinks - MSN
Q4 EPS Estimates for GeoVax Labs Lifted by Noble Financial - Defense World
GeoVax Announces Positive Interim Data Review for Phase 2 - GlobeNewswire
GeoVax regains compliance with Nasdaq listing standards By Investing.com - Investing.com Australia
GeoVax regains compliance with Nasdaq listing standards - Investing.com India
GeoVax reports progress in CLL vaccine booster trial - Investing.com India
GeoVax reports progress in CLL vaccine booster trial By Investing.com - Investing.com Canada
GeoVax Labs announces interim data from Phase 2 trial of Vaccine technology - TipRanks
GeoVax's COVID Booster Shows Promise in Leukemia Patients, Outperforms mRNA Vaccine | GOVX Stock News - StockTitan
GeoVax Announces Positive Interim Data Review for Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia - Yahoo Finance
Analysts Set Expectations for GeoVax Labs FY2024 Earnings - Defense World
Earnings call: GeoVax reports progress in vaccine trials, financial updates By Investing.com - Investing.com Australia
ARMISTICE CAPITAL, LLC Expands Stake in Geovax Labs Inc - GuruFocus.com
Brokerages Set GeoVax Labs, Inc. (NASDAQ:GOVX) PT at $12.67 - Defense World
GeoVax Labs, Inc. (NASDAQ:GOVX) Q3 2024 Earnings Call Transcript - MSN
Earnings call: GeoVax reports progress in vaccine trials, financial updates - Investing.com
U.S. Stock market top losers: Gaucho Group Holdings sees decline of 55.06% while GeoVax Labs looses 23.53% in early trading - Business Upturn
Geovax Labs Inc (GOVX) Q3 2024 Earnings Call Highlights: Strategic Advances and Financial Challenges - Yahoo Finance
Alliance Global Partners Initiates Coverage on GeoVax Labs (NASDAQ:GOVX) - Defense World
GeoVax Labs Reports Improved Earnings and Strategic Progress - TipRanks
GeoVax Labs reports Q3 EPS (91c), consensus ($1.48) - TipRanks
GeoVax Reports Progress on COVID-19 Vaccine and Cancer Therapies in Q3 2024 Financial Results - Citybuzz
GeoVax Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
GeoVax Q3 Loss Narrows to $5.8M as BARDA Contract Boosts Revenue to $2.8M | GOVX Stock News - StockTitan
GeoVax Labs initiated with a Buy at Alliance Global Partners - Yahoo Finance
This GeoVax Labs Analyst Begins Coverage On A Bullish Note; Here Are Top Initiations For Monday - Benzinga
GeoVax to Report Third Quarter 2024 Financial Results and Provide Corporate Update on November 12, 2024 - GlobeNewswire
Should You Buy GeoVax Labs Inc. (GOVX) After Golden Cross? - MSN
GeoVax expands offering size to $30 million By Investing.com - Investing.com Australia
GeoVax expands offering size to $30 million - Investing.com India
Geovax Labs Inc Azioni (GOVX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.60%
2.24%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):